Skip to content
10-Q

Quarterly Report

Rapid Therapeutic Science Laboratories, Inc.

0001393905-23-000220

← back to feed
Filed
May 12, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 12, 2023 8.08M sh
Capex Q1 2023 · Mar 31, 2023 $0
Capex restated Q1 2023 · Mar 31, 2022 $35.2K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$41.81K
Operating Cash Flow restated Q1 2023 · Mar 31, 2022 −$699.42K
Cash And Equivalents Q1 2023 · Mar 31, 2023 $17.57K
Cash And Equivalents Q1 2023 · Dec 31, 2022 $0
Stockholders Equity Q1 2023 · Mar 31, 2023 −$2.84M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$3.14M
Current Liabilities Q1 2023 · Mar 31, 2023 $4.46M
Current Liabilities Q1 2023 · Dec 31, 2022 $4.97M
Total Liabilities Q1 2023 · Mar 31, 2023 $4.87M
Total Liabilities Q1 2023 · Dec 31, 2022 $5.4M
Current Assets Q1 2023 · Mar 31, 2023 $250.77K
Current Assets Q1 2023 · Dec 31, 2022 $233.19K
Total Assets Q1 2023 · Mar 31, 2023 $2.03M
Total Assets Q1 2023 · Dec 31, 2022 $2.25M
Eps Basic Q1 2023 · Mar 31, 2023 $0.02
Eps Basic Q1 2023 · Mar 31, 2022 −$0.20
Sga Expense Q1 2023 · Mar 31, 2023 $92.3K
Sga Expense restated Q1 2023 · Mar 31, 2022 $783.4K
Gross Profit Q1 2023 · Mar 31, 2023 $0
Gross Profit Q1 2023 · Mar 31, 2022 $0
Cost Of Revenue Q1 2023 · Mar 31, 2023 $0
Cost Of Revenue Q1 2023 · Mar 31, 2022 $0
Revenue Q1 2023 · Mar 31, 2023 $0
Revenue Q1 2023 · Mar 31, 2022 $0